Whole-genome characterization of chemoresistant ovarian cancer.
about
Cytotoxic and targeted therapy for hereditary cancersGenomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical PracticeNovel Molecular Markers for Breast CancerStrategies for Integrated Analysis of Genetic, Epigenetic, and Gene Expression Variation in Cancer: Addressing the ChallengesCancer Evolution and the Limits of Predictability in Precision Cancer MedicineGenetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapyDifferent Facets of Copy Number Changes: Permanent, Transient, and AdaptiveRethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancerHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerDNA methylation changes in epithelial ovarian cancer histotypes.Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and TreatmentUse of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinicChemoresistance and targeted therapies in ovarian and endometrial cancersUpdate on immune checkpoint inhibitors in gynecological cancersMajor clinical research advances in gynecologic cancer in 2015The role of immune checkpoint inhibition in the treatment of ovarian cancerTargeted next-generation sequencing for molecular diagnosis of endometriosis-associated ovarian cancerMAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomasThe Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian CancerDifferential network analysis from cross-platform gene expression data.The temporal dynamics of chromosome instability in ovarian cancer cell lines and primary patient samples.RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT.Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancerMethylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency.Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs.Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.Point Mutations in Exon 1B of APC Reveal Gastric Adenocarcinoma and Proximal Polyposis of the Stomach as a Familial Adenomatous Polyposis Variant.Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review.The milk-derived fusion peptide, ACFP, suppresses the growth of primary human ovarian cancer cells by regulating apoptotic gene expression and signaling pathways.Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.Suppression of ABHD2, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancerChallenges in identifying cancer genes by analysis of exome sequencing data.Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform.Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis.Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics.The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE".
P2860
Q26739366-32950508-1BF5-4594-8421-7481CD849F4DQ26740622-CC1F8FB7-5D11-42F1-A903-73CD0706F456Q26753160-3BF07B6D-86CD-48B0-8F19-DF74A273C0E3Q26766390-DE29257B-33CC-4F81-8B1C-49DFCB385E53Q26767415-BD41EF7D-0BB3-4377-824D-713AC39A04B5Q26769604-B10BAE37-E35F-4908-A727-F3AA8EE1F982Q26769649-C29E5B53-4B47-4E35-9763-24E6164B15C3Q26780387-10ADE654-FF73-4549-B168-F7835F619A62Q26783551-6EBF6863-B069-405E-A90F-9933C8EDF547Q27690722-FA430A0B-F5C4-43CC-9F9D-D5E311EAC72EQ28066904-854B4E72-1D6C-4FF9-8EE2-573A9BB703C7Q28071541-34F983E1-B533-4A6D-8967-A030BE8B2C66Q28073246-E540A5B0-1D79-4BA2-9884-38AA4F4AB4DDQ28076497-1084E07B-8F27-4075-9BD6-E0443A1D0712Q28077183-442D8597-FE2D-48E9-A6D4-FBAD5D68DA84Q28077924-CD0DBCA0-3422-464C-9E94-1844B9EAC166Q28273722-03B9A62F-E419-4899-B5EE-E3693A20C90AQ28393224-D09F7172-46A8-4AD1-9506-9C056C2294F8Q28833833-6F42ECDF-6A6F-4B95-8C92-BBE09A649B87Q31133441-6248DDB0-BDBD-4D60-9FFE-8C43E48EC4F4Q33574500-7D7DE878-88D9-4D4D-95BF-58D4DAA98A47Q33591552-239484A4-BC97-4E9F-8823-DC71D488E564Q33688593-9E05494E-D463-4DEA-99B8-58E9F912D510Q33704050-2B9B3FBD-B211-4FE1-871A-13561F5053D6Q33827681-E3EB7A21-4623-4D88-AF25-F1A31439139CQ33829756-0322EB77-C3F9-4DF1-8E39-DF4F1578889AQ33841579-2671DD5D-D194-4AF9-A68B-5571F253DB03Q33880847-322FF9A0-EDC8-4279-A3F3-8B1FE5440E28Q34500340-A93D87ED-5B3F-4B94-ABF5-DA70039388BAQ34514973-42C75C5F-B7D9-4FAE-8EB1-DF0C88FA7D1BQ34522502-7E350D80-E47A-4A1E-BAD6-ECA515FDD3C1Q34529131-B11108C8-6094-498B-8C51-FF8C60EDAC23Q35969753-81212D99-AFBD-4837-9A88-8B7264E1BFD8Q36021163-958B1AC2-903E-4E09-9647-9A3496734761Q36057092-5353B34D-1DCE-4AAC-8610-8A673ACDA25BQ36078151-1CA1CE28-D30B-45E6-9734-DD97B51AF081Q36088140-584069BC-9EA5-4660-BD68-C893132EF2D8Q36182381-E21B5B6B-58A9-4555-AD06-9A9CF9E1D141Q36199823-0DEF38DB-1A50-435D-9D9B-332AFA8A9280Q36233893-085FA294-A495-47D3-88F9-5AFC1059A48C
P2860
Whole-genome characterization of chemoresistant ovarian cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Whole-genome characterization of chemoresistant ovarian cancer.
@en
Whole-genome characterization of chemoresistant ovarian cancer.
@nl
type
label
Whole-genome characterization of chemoresistant ovarian cancer.
@en
Whole-genome characterization of chemoresistant ovarian cancer.
@nl
prefLabel
Whole-genome characterization of chemoresistant ovarian cancer.
@en
Whole-genome characterization of chemoresistant ovarian cancer.
@nl
P2093
P2860
P50
P356
P1433
P1476
Whole-genome characterization of chemoresistant ovarian cancer.
@en
P2093
Andrea Jewell
Andrew Lonie
Ann-Marie Patch
Anne Hamilton
Barsha Poudel
Catherine Kennedy
Chris Mitchell
Collin Stewart
Conrad Leonard
Craig Nourse
P2860
P2888
P304
P356
10.1038/NATURE14410
P407
P50
P577
2015-05-01T00:00:00Z